Boston Scientific Corporation  (BSX)
Other Ticker:  
Price: $39.8900 $0.67 1.708%
Day's High: $40.02 Week Perf: -3.46 %
Day's Low: $ 39.64 30 Day Perf: -9.13 %
Volume (M): 265 52 Wk High: $ 47.50
Volume (M$): $ 10,498 52 Wk Avg: $43.05
Open: $39.25 52 Wk Low: $37.96

 Market Capitalization (Millions $) 57,378
 Shares Outstanding (Millions) 1,438
 Employees 36,000
 Revenues (TTM) (Millions $) 12,162
 Net Income (TTM) (Millions $) 810
 Cash Flow (TTM) (Millions $) -1,724
 Capital Exp. (TTM) (Millions $) 600

Boston Scientific Corporation
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties, including interventional cardiology, peripheral interventions, neurovascular intervention, electrophysiology, vascular surgery, endoscopy, oncology, urology and gynecology. Since the Company was formed in 1979, it has advanced the practice of less-invasive medicine by providing a broad portfolio of innovative products, technologies and services across a wide range of medical specialties. The Company's products are generally inserted into the human body through natural openings or small incisions in the skin and can be guided to most areas of the anatomy to diagnose and treat a wide range of medical problems. These products help physicians and other medical professionals improve their patients' quality of life by providing alternatives to surgery.

The Company's broad innovative product offerings have enabled it to become a leader in the interventional cardiology market. Leadership is in part due to its coronary stent product offerings. Coronary stents are tiny, mesh tubes used in the treatment of coronary artery disease and implanted in patients to prop open arteries and facilitate blood flow from the heart. The Company, however, looked to further enhance the outcomes associated with the use of coronary stents, particularly the processes that lead to in-stent restenosis (the growth of neointimal tissue within an artery after angioplasty and stenting), through dedicated internal and external product development and scientific research. The Company believes that the combination of certain drugs and coronary stents offers the opportunity for a more lasting solution for coronary artery disease.

The Company's products are offered for sale by two dedicated business groups - Cardiovascular and Endosurgery. The Cardiovascular organization focuses on products and technologies for use in interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, and neurovascular procedures. The Endosurgery organization focuses on products and technologies for use in oncology, endoscopy, urology and gynecology procedures.

Boston Scientific announced a master branding initiative. This initiative marks the Company's evolution from a collection of divisional identities into one, unified organization. The master brand will enable the Company to strengthen recognition of the Boston Scientific name and build equity in that name.

The Company sold its products to over 10,000 hospitals, clinics, out-patient facilities and medical offices. The Company is not dependent on any single institution

The Company also distributes certain products for third parties, including an introducer sheath, certain guidewires and acellular tissue for use in connection with urology and gynecology procedures.


Internationally, the Company operates through three business segments divided among the geographic regions of Europe, Japan and Inter-Continental.


The Company encounters significant competition across its product lines and in each market in which its products are sold from various entities, some of which may have greater financial and marketing resources than the Company. The Company's primary competitors include: Abbott Laboratories, Inc., Cook, Inc., Guidant Corporation (including its subsidiary Advanced Cardiovascular Systems, Inc.), Johnson & Johnson (including its subsidiary, Cordis Corporation), and Medtronic, Inc. (including its subsidiary, Medtronic AVE, Inc.), as well as a wide range of companies which sell a single or limited number of competitive products or participate only in specific market segment.

   Company Address: 300 Boston Scientific Way Marlborough 1752 MA
   Company Phone Number: 683-4000   Stock Exchange / Ticker: NYSE BSX
   BSX is expected to report next financial results on August 05, 2022.

Customers Net Income fell by BSX's Customers Net Profit Margin fell to

-1.9 %

2.12 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

Year to Date Decrease / Increase
EW   -26.51%    
SYK   -13.18%    
ABT   -17.27%    
DHR   -19.84%    
JNJ        4.61% 
• View Complete Report

Sunworks Inc.

Company Fail to Break-even Despite Surge in Sales

Sunworks Inc announced very strong Sales growth of 405.69% year on year to $31.20 millions in the first quarter of 2022, but loss increased at $-0.28.

Aixin Life International Inc.

Aixin Life International Inc announced financial period ending Mar 31 2022 operating loss of $-0.772154 millions

Aixin Life International Inc announced very strong Sales growth of 362.73% year on year to $0.42 millions in the financial period ending Mar 31 2022, but increased losses at $-0.02.

Aerovate Therapeutics Inc.

Logged a Loss but Revenues Unchanged at Aerovate Therapeutics Inc in the first quarter of 2022

In the first quarter of 2022 Aerovate Therapeutics Inc lost money of $-0.45 per share compared to $-1.87 a year ago and eps fell from $0.94 per share from the previous quarter.

Celsion Corporation

Losses Widen but Revenues Unchanged

In the first quarter of 2022 Celsion Corporation increased losses of $-1.82 per share compared to $-0.08 a year ago and increased losses from $-0.02 per share from the previous quarter.

Forge Innovation Development Corp.

Forge Innovation Development Corp reported financial period ending Mar 31 2022 operating loss of $-0.030757 millions

In the financial period ending Mar 31 2022 Forge Innovation Development Corp reached break-even of $0.00 per share compared to $-0.01 a year ago and from $-0.00 per share from the previous quarter.


Boston Scientific's Segments
 Segment    30.09 % of total Revenue
 Segment    3.33 % of total Revenue
 Segment    43.53 % of total Revenue
 Segment    19.77 % of total Revenue
 Segment    19.77 % of total Revenue
 Segment    6.99 % of total Revenue
Cardiac Rhythm Management
 Segment    26.38 % of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Boston Scientific does not provide revenue guidance.

Earnings Outlook
Forge Innovation Development Corp. does not provide earnings estimates.

Geographic Revenue Dispersion
United States 52.67 %
Asia Pacific 9.19 %
Other countries 38.14 %


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

IONQ's Profile

Stock Price

IONQ's Financials

Business Description


Charts & Quotes

IONQ's News


IONQ's Competitors

Customers & Markets

Economic Indicators

IONQ's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071